BYSI - BeyondSpring Inc.
NASDAQ
->
Healthcare
->
Biotechnology
New York,
United States
Type: Equity
BYSI price evolution
BYSI
| (in millions $) | 30 Jul 2024 | 31 Jan 2024 | 30 Jul 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $14.92 | $18.42 | $25.79 | $38.52 |
| Long term investments | ||||
| Property, plant & equipment | $5.54 | $6.03 | $6.75 | $7.35 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $20.9 | $24.81 | $32.88 | $46.22 |
| Current liabilities | ||||
| Accounts payable | $2.12 | $1.41 | $1.5 | $1.08 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $8.19 | $7.96 | $6.82 | $7.35 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $51.08 | $51.61 | $50.97 | $52.2 |
| Shareholders' equity | ||||
| Retained earnings | -$403.56 | -$396.3 | -$388 | -$375.28 |
| Other shareholder equity | $1.26 | $0.89 | $1.22 | $0.44 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $41.63 | $109.54 | ||
| Short term investments | $17.57 | |||
| Net receivables | $3.5 | |||
| Inventory | ||||
| Total current assets | $38.52 | $75.12 | $113.4 | |
| Long term investments | ||||
| Property, plant & equipment | $7.35 | $3.41 | $2.36 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $3.64 | |||
| Total investments | ||||
| Total assets | $46.22 | $81.65 | $117.04 | |
| Current liabilities | ||||
| Accounts payable | $1.08 | $1.66 | $2.22 | |
| Deferred revenue | $1.35 | |||
| Short long term debt | $1.57 | |||
| Total current liabilities | $7.35 | $15.15 | $13.77 | |
| Long term debt | $2.17 | |||
| Total noncurrent liabilities | $16.65 | |||
| Total debt | ||||
| Total liabilities | $52.2 | $55.27 | $25.22 | |
| Shareholders' equity | ||||
| Retained earnings | -$375.28 | -$342 | -$277.82 | |
| Other shareholder equity | $0.44 | -$0.52 | -$0.3 | |
| Total shareholder equity | $26.68 | $88.34 | ||
| (in millions $) | 30 Jul 2024 | 31 Jan 2024 | 30 Jul 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1 | $1.75 | $0.88 | $1.35 |
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $8.42 | $24.86 | $14.36 | $38.59 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.11 | -$0.01 | $0.16 | |
| Interest expense | -$0.04 | $0.3 | $0.08 | -$0.25 |
| Net income | ||||
| Net income | -$7.26 | -$21.03 | -$12.72 | -$33.28 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.75 | $1.35 | $0.18 | |
| Cost of revenue | ||||
| Gross Profit | $0.18 | |||
| Operating activities | ||||
| Research & development | $41.79 | |||
| Selling, general & administrative | $22.6 | |||
| Total operating expenses | $24.86 | $38.59 | $64.39 | |
| Operating income | -$64.21 | |||
| Income from continuing operations | ||||
| EBIT | -$64.21 | |||
| Income tax expense | $0.11 | $0.16 | ||
| Interest expense | $0.3 | -$0.25 | -$0.09 | |
| Net income | ||||
| Net income | -$21.03 | -$33.28 | -$60.97 | |
| Income (for common shares) | -$60.97 | |||
| (in millions $) | 31 Jan 2023 | 30 Dec 2021 | 29 Sep 2021 | 30 Jul 2021 |
|---|---|---|---|---|
| Net income | -$9.51 | -$18.37 | -$37.34 | |
| Operating activities | ||||
| Depreciation | $0.01 | $0.02 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$16.92 | $2.83 | -$33.15 | |
| Investing activities | ||||
| Capital expenditures | -$2.81 | -$0.02 | ||
| Investments | -$1.92 | $9.36 | ||
| Total cash flows from investing | $18.25 | -$4.73 | $9.34 | -$25.02 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $3.43 | $0 | ||
| Effect of exchange rate | -$0.76 | -$0.16 | -$0.04 | -$0.06 |
| Change in cash and equivalents | -$7.23 | -$21.81 | $12.13 | -$58.23 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Net income | -$64.18 | -$60.97 | ||
| Operating activities | ||||
| Depreciation | $0.06 | $0.08 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$47.24 | -$43.74 | ||
| Investing activities | ||||
| Capital expenditures | -$2.84 | -$0.05 | ||
| Investments | -$17.57 | |||
| Total cash flows from investing | -$0.1 | $18.25 | -$20.41 | -$0.05 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | $0.61 | |||
| Total cash flows from financing | $0 | $3.43 | $0 | $117.83 |
| Effect of exchange rate | -$0.08 | -$0.76 | -$0.26 | -$0.43 |
| Change in cash and equivalents | -$16.65 | -$7.23 | -$67.91 | $73.6 |
News
Fundamentals
| Market cap | $89.06M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 40.30M |
| Revenue | $4.98M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$74.29M |
| Revenue Q/Q | 47.93% |
| Revenue Y/Y | N/A |
| P/E ratio | -1.20 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 17.90 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.84 |
|---|---|
| ROA | -238.09% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.82 |
| Quick ratio | N/A |